Merrion Finalises Its Phase III Development Program for Orazol(TM) in the USA

DUBLIN, Ireland, Nov. 16, 2010 (GLOBE NEWSWIRE) — After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol™. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA’s abbreviated approval procedure section 505(b)(2) using a single [...] http://bit.ly/cxo8fX